USTR: Nothing in USMCA will lead to higher drug prices for U.S. consumers

After fielding several concerns from Democratic lawmakers, the Office of the U.S. Trade Representative on Monday rebutted claims that provisions in the U.S.-Mexico-Canada Agreement would lead to higher drug prices for U.S. consumers. “It is important to note that nothing in the newly negotiated USMCA will require changing U.S. laws on pharmaceutical intellectual property rights or lead to higher prices on drugs for U.S. consumers,” USTR said in a March 25 statement . “We look forward to working with Congress...